Compare GRDN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | IMCR |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United Kingdom |
| Employees | 3400 | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | N/A | 2016 |
| Metric | GRDN | IMCR |
|---|---|---|
| Price | $34.39 | $30.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $37.33 | ★ $61.82 |
| AVG Volume (30 Days) | 246.1K | ★ 358.8K |
| Earning Date | 03-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $1.13 | $14.39 |
| Revenue Next Year | $9.97 | $8.19 |
| P/E Ratio | $117.77 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $19.17 | $23.15 |
| 52 Week High | $37.43 | $40.71 |
| Indicator | GRDN | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 37.46 |
| Support Level | $27.73 | N/A |
| Resistance Level | $36.13 | $34.86 |
| Average True Range (ATR) | 1.91 | 1.42 |
| MACD | 0.01 | -0.24 |
| Stochastic Oscillator | 67.25 | 10.17 |
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.